Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.

Mathew VithayathilAntonio D'AlessioClaudia Angela Maria FulgenziNaoshi NishidaMartin SchönleinJohann von FeldenKornelius SchulzeHenning WegeAnwaar SaeedBrooke WietharnHannah HildebrandLinda WuCelina AngThomas U MarronArndt WeinmannPeter R GalleDominik BettingerBertram BengschArndt VogelLorenz BalcarBernhard ScheinerPei-Chang LeeYi-Hsiang HuangSuneetha AmaraMahvish MuzaffarAbdul Rafeh NaqashAntonella CammarotaValentina ZanusoTiziana PressianiMatthias PinterAlessio CortelliniMasatoshi KudoLorenza RimassaDavid J PinatoRohini Sharma

Published in: Hepatology international (2023)

Atezo/Bev has comparable efficacy in overweight HCC patients, with an increase in treatment-related fatigue and thrombosis. Combination therapy is safe and efficacious to use in overweight patients, including those with underlying NAFLD.

Keyphrases

combination therapy
body mass index
end stage renal disease
weight gain
physical activity
weight loss
chronic kidney disease
ejection fraction
newly diagnosed
pulmonary embolism
peritoneal dialysis
sleep quality
depressive symptoms
replacement therapy